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a b s t r a c t
The transcription factor Nrf2 regulates the basal and inducible expression of a battery of cytoprotective
genes. Whereas numerous Nrf2-inducing small molecules have been reported, very few chemical
inhibitors of Nrf2 have been identiﬁed to date. The quassinoid brusatol has recently been shown to
inhibit Nrf2 and ameliorate chemoresistance in vitro and in vivo. Here, we show that brusatol provokes a
rapid and transient depletion of Nrf2 protein, through a posttranscriptional mechanism, in mouse Hepa-
1c1c7 hepatoma cells. Importantly, brusatol also inhibits Nrf2 in freshly isolated primary human
hepatocytes. In keeping with its ability to inhibit Nrf2 signaling, brusatol sensitizes Hepa-1c1c7 cells to
chemical stress provoked by 2,4-dinitrochlorobenzene, iodoacetamide, and N-acetyl-p-benzoquinone
imine, the hepatotoxic metabolite of acetaminophen. The inhibitory effect of brusatol toward Nrf2 is
shown to be independent of its repressor Keap1, the proteasomal and autophagic protein degradation
systems, and protein kinase signaling pathways that are known to modulate Nrf2 activity, implying the
involvement of a novel means of Nrf2 regulation. These ﬁndings substantiate brusatol as a useful
experimental tool for the inhibition of Nrf2 signaling and highlight the potential for therapeutic
inhibition of Nrf2 to alter the risk of adverse events by reducing the capacity of nontarget cells to buffer
against chemical and oxidative insults. These data will inform a rational assessment of the risk:beneﬁt
ratio of inhibiting Nrf2 in relevant therapeutic contexts, which is essential if compounds such as brusatol
are to be developed into efﬁcacious and safe drugs.
& 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).
Introduction
The redox-sensitive transcription factor nuclear factor erythroid
2-related factor 2 (Nrf2)2 plays a critical role in the regulation
of cellular defense against chemical and oxidative stress [1]. The
activity of Nrf2 is primarily governed by its physical and functional
interaction with the cytosolic repressor Kelch-like ECH-associated
protein 1 (Keap1), which facilitates the ubiquitination and subse-
quent proteasomal degradation of Nrf2 via the Cullin 3 ubiquitin
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ligase complex [2,3]. Upon exposure to chemical or oxidative
stresses, the ability of Keap1 to repress Nrf2 is disrupted, leading
to the latter's accumulation and translocation to the nucleus, where
Nrf2 induces the transcription of a battery of cytoprotective genes
encoding redox-balancing proteins, phase II detoxiﬁcation enzymes,
and drug transporters [4]. In doing so, Nrf2 promotes the main-
tenance of cellular homeostasis under stress conditions. Exemplifying
the above, transgenic Nrf2-knockout mice demonstrate enhanced
susceptibility to various drug-induced toxicities, including acetami-
nophen hepatotoxicity [5,6], cisplatin nephrotoxicity [7], and bleo-
mycin lung ﬁbrosis [8], whereas genetic knockdown of Keap1 confers
a protective phenotype [9].
Recently, a number of studies have demonstrated a link between
oncogenesis and mutations in the Keap1 and/or Nrf2 genes that result
in the constitutive activation of Nrf2 [10]. In keeping with its ability to
protect against chemical and oxidative stress, the constitutive activa-
tion of Nrf2 has also been shown to contribute to the development of
drug resistance in cancer cell lines and tissues [11]. As a result, there is
a burgeoning interest in the therapeutic potential of inhibiting Nrf2 as
a strategy for overcoming chemoresistance. A barrier to this goal is the
paucity of small-molecule inhibitors of Nrf2 that have been described
to date, whereas the consequences for nontarget cell health of
inhibiting Nrf2, particularly in the context of cytotoxic cancer therapy,
have yet to be fully considered.
The quassinoid brusatol, isolated from the Brucea javanica plant,
has recently been shown to inhibit Nrf2 signaling, reduce tumor
burden, and ameliorate chemoresistance in both in vitro and in vivo
cancer models [12–14]. Here, using Hepa-1c1c7 hepatoma cells and
freshly isolated primary human hepatocytes, we demonstrate that
brusatol provokes a rapid and transient depletion of Nrf2 protein,
through a posttranscriptional mechanism that is independent of
Keap1, the proteasomal and autophagic protein degradation sys-
tems, and protein kinase signaling pathways that are known to
regulate Nrf2. In keeping with its ability to inhibit Nrf2 signaling,
we show that brusatol sensitizes Hepa-1c1c7 cells to chemical
stress provoked by 2,4-dinitrochlorobenzene (DNCB), iodoaceta-
mide (IAA), and N-acetyl-p-benzoquinone imine (NAPQI), the hepa-
totoxic metabolite of acetaminophen. Therefore, whereas brusatol is
a valuable experimental tool for inhibiting Nrf2, the beneﬁt:risk
ratio of its therapeutic use should be considered in light of the
potential for enhanced sensitivity of nontarget cells to endogenous
and exogenous chemical and oxidative insults.
Materials and methods
Materials
Brusatol was extracted and puriﬁed from fractions generated
from dried plant material of Fructus Bruceae using Diaion HP-20,
Diaion HP-20ss, and Sephadex LH-20 column chromatography and
puriﬁed using a C18 semipreparative HPLC column (Alltima C18
column, 10250 mm, 5 mm). The structure of brusatol was con-
ﬁrmed by NMR using a Bruker NMR spectrometer (400 MHz) with
trimethylsilane as the internal standard. The structure was further
conﬁrmed by APCI–MS using an Agilent HP 1100 series SL Trap MSD.
Methyl 2-cyano-3,12-dioxooleana-1,9(11)dien-28-oate (CDDO-Me)
was kindly provided by Dr. Michael Wong and Professor Paul
O’Neill (Department of Chemistry, University of Liverpool). All other
materials were obtained from Sigma–Aldrich (UK).
Hepa-1c1c7 cell culture
Mouse Hepa-1c1c7 hepatoma cells were maintained in Dulbecco's
modiﬁed Eagle's medium supplemented with 584 mg/L L-glutamine,
10% (v/v) heat-inactivated fetal bovine serum (FBS; Biowest, France),
100 U/ml penicillin, and 100 mg/ml streptomycin, at 37 1C in a 5% CO2
humidiﬁed environment.
Primary human hepatocyte isolation and culture
Liver tissue was obtained from the Liver Cell Lab at the Karolinska
University Hospital (Huddinge, Sweden) or Aintree University Hospital
(Liverpool, UK) by qualiﬁed medical staff, with donor informed
consent following local ethical and institutional guidelines. The liver
tissue used in this study was obtained from four patients (PHH1–4, see
Supplementary Table S1 for details) undergoing planned liver resec-
tion for various indications. Immediately after removal from the
patient, excess healthy liver parenchyma was separated from the
specimen and placed in cold Eagle's minimum essential medium and
transported to the laboratory on ice. Tissue dissociation and hepato-
cyte isolation were performed by using a two-step collagenase
perfusion procedure, essentially as described previously [15]. The cells
were counted and a Trypan blue exclusion test was used to calculate
viability. The cell suspension was diluted to the required density in
William's medium E without phenol red, supplemented with 25 mM
Hepes and 2mM L-glutamine, pH adjusted to 7.4 (modiﬁed William's
medium E) supplemented with 10% FBS. Cells were seeded onto type I
collagen-coated plates and cultured at 37 1C in a 5% CO2 humidiﬁed
environment. After 3 h, the mediumwas replaced with fresh modiﬁed
William's medium E not supplemented with FBS, and the cells were
cultured for a further 16 h before commencement of experiments.
Cell treatments
Cells were seeded into appropriate culture plates 24 h before
the start of the experiments. All compounds were dissolved in
dimethyl sulfoxide (DMSO) before addition to the cell culture
medium, and the concentration of the vehicle was maintained at
0.5% (v/v) regardless of drug concentration.
Immunoblotting
Cells were lysed in radioimmunoprecipitation assay buffer, and
clariﬁed whole-cell lysates were resolved by denaturing electrophor-
esis on 4–12% Novex Bis–Tris polyacrylamide gels (Life Technologies,
UK). Separated proteins were transferred onto Hybond nitrocellulose
membranes (GE Healthcare, UK), which were then blocked in Tris-
buffered saline (TBS; pH 7.0) containing 0.1% Tween 20 and 10% nonfat
milk (Bio-Rad). Blocked membranes were probed in TBS containing
0.1% Tween 20 and 2% nonfat milk supplemented with antibodies
raised against Nrf2 (EP1808Y; Abcam, UK), β-actin (AC-15; Abcam),
Keap1 (sc-15246; Santa Cruz Biotechnology, Germany), p62/SQSTM1
(P0067; Sigma–Aldrich), cyclin A (sc-751; Santa Cruz Biotechnology),
hypoxia-inducible factor 1α (HIF-1α; 610959; BD Biosciences, UK), p53
(M7001; Dako, UK), survivin (sc-17779; Santa Cruz Biotechnology),
phospho-p38 MAPK (4511S; Cell Signaling Technology), phospho-AKT
(4060S; Cell Signaling Technology), phospho-ERK1/2 (4377S; Cell
Signaling Technology), and phospho-SAPK (9251S; Cell Signaling
Technology). Horseradish peroxidase-linked anti-rabbit (A9169;
Sigma–Aldrich), anti-mouse (A9044; Abcam), and anti-goat (P0449;
Dako) secondary antibodies were used as necessary. Immunoblots
were visualized by enhanced chemiluminescence (PerkinElmer, UK)
and exposed to Hyperﬁlm ECL (Amersham). Immunoreactive band
volumes were quantiﬁed using TotalLab 100 software (Nonlinear
Dynamics, UK) and normalized to β-actin.
Measurement of cellular ATP content
Cell viability was measured using the CellTiter-Glo lumines-
cence assay (Promega, UK), in accordance with the manufacturer's
instructions.
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Real-time RT-PCR
Total RNA was extracted from cells and puriﬁed using an
RNeasy Mini Kit from Qiagen, according to the manufacturer's
instructions. cDNA was synthesized using the ImProm-II reverse
transcription system (Promega) according to the manufacturer's
instructions. Real-time quantitative PCR (RT-qPCR) analysis of the
Nrf2, Keap1, NAD(P)H dehydrogenase quinone 1 (Nqo1), glutamate
Fig. 1. Rapid and transient posttranscriptional inhibition of Nrf2 by brusatol. (A and B) Nrf2 protein levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to
(A) the indicated concentrations of brusatol for 2 h or (B) 300 nM brusatol for the indicated times, as determined by immunoblotting. All blots shown are representative of
three independent experiments. Nrf2 levels were quantiﬁed by densitometry, normalized to the loading control, β-actin, and expressed as a percentage of the Nrf2 level
detected (A) in vehicle-exposed cells or (B) at 0 h. (C) Nrf2 mRNA level in Hepa-1c1c7 cells exposed to 300 nM brusatol for the indicated times, as determined by RT-qPCR.
Nrf2 levels were normalized to the loading control, Gapdh, and expressed as a percentage of the Nrf2mRNA level detected at 0 h. (D) Superimposition of the time-course data
for Nrf2 protein and mRNA presented in (B) and (C). (E) ATP content in Hepa-1c1c7 cells exposed to the indicated concentrations of brusatol for 2 or 24 h. ATP levels are
expressed as a percentage of the ATP content of vehicle-exposed cells. All data represent the mean þ SD of n¼3 independent experiments. Statistical analyses were
performed using an unpaired t test (*Po0.05, **Po0.01, ***Po0.001 vs vehicle or 0 h control).
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cysteine ligase regulatory subunit (Gclm), and glyceraldehyde-3-
phosphate dehydrogenase (Gapdh) genes was performed on a ABI
Prism 7000 real-time PCR instrument using Applied Biosystems
(UK) SYBR green PCR master mix. Gapdh was used as a normal-
ization control. Primer sequences are detailed in Supplementary
Table S2.
Real-time imaging of Nrf2–Venus
An SK-N-AS cell line stably expressing Nrf2–Venus under
control of the endogenous human Nrf2 promoter region was
kindly provided by Professor M. White (University of Manchester,
UK). For live-cell imaging experiments, cells were seeded onto 35-
mm glass-bottom dishes (Iwaki, Japan) before being exposed to
100 nM CDDO-Me for 1 h, followed by 300 nM brusatol. Nrf2–
Venus expression was recorded at 2-min intervals by confocal
microscopy, which was performed on a Zeiss LSM 780 microscope
using a 20 plan-Apochromat objective. Cells were maintained in
a humidiﬁed microscope stage incubator at 37 1C with 5% CO2
throughout the experiment.
RNA interference
A small interfering RNA (siRNA) duplex targeted against mouse
Keap1 and a scrambled, nontargeting control duplex (D-001210-
03) were purchased from the Dharmacon siGENOME library. Cells
were transfected for 48 h with 10 nM siRNA using Lipofectamine
RNAiMAX (Life Technologies), according to the manufacturer's
instructions.
Measurement of proteasome activity
The human 20S proteasome was obtained from Enzo Life
Sciences, and 1 mg of puriﬁed protein was preincubated for 30 min
at 37 1C with the indicated concentrations of brusatol or MG132 in
50 mM Hepes (pH 7.8). Probe substrates for trypsin-like (Boc-LSTR-
AMC, 50 mM; Sigma–Aldrich), chymotrypsin-like (Suc-LLVY-AMC,
50 mM; Enzo Life Sciences, UK), or caspase-like (Z-LLE-AMC,
400 mM; Enzo Life Sciences) activity were subsequently added and
substrate cleavage was determined by quantiﬁcation of 7-amino-4-
methylcoumarin (AMC) ﬂuorescence (excitation 360 nm, emission
460 nm) over 8 h and referenced to an AMC standard curve.
Statistical analysis
Where applicable, data are expressed as the mean þ standard
deviation of the mean (SD) from n¼3 independent experiments.
The signiﬁcance of differences between relevant data sets was
assessed with an unpaired t test. A two-sided P value of r0.05
was considered statistically signiﬁcant.
Results
Rapid and transient posttranscriptional inhibition of Nrf2 by brusatol
To conﬁrm that brusatol inhibits Nrf2, mouse Hepa-1c1c7 cells
were exposed to a range of concentrations of the compound, and
whole-cell Nrf2 levels were determined by immunoblotting.
Within 2 h of exposure to cells, brusatol provoked the depletion
of Nrf2, in a concentration-dependent manner (Fig. 1A). A detailed
examination of the time course of the effect of brusatol on Nrf2
revealed a signiﬁcant depletion of the transcription factor in as
little as 30 min after exposure of the cells to brusatol (Fig. 1B).
Notably, the inhibitory effect of brusatol on Nrf2 was transient in
nature, as the resting level of Nrf2 was restored within 12 h of
initial exposure to the compound (Fig. 1B). Moreover, there was
evidence for a compensatory increase in Nrf2 protein, above the
resting level, 24 h after exposure to brusatol (Fig. 1B). The rapid
depletion of Nrf2 protein provoked by brusatol was not associated
with a decrease in the level of Nrf2 mRNA (Fig. 1C), indicating that
the effect on protein abundance is posttranscriptional. However, at
later time points there was a signiﬁcant increase in the level of
Nrf2 mRNA, which reached a peak between 4 and 8 h after the
initial exposure to brusatol (Fig. 1C). Superimposition of the mRNA
and protein data indicated that the increase in Nrf2 mRNA
immediately preceded the recovery of Nrf2 protein toward the
resting level (Fig. 1D), implying that the transient nature of the
Nrf2 inhibition provoked by brusatol is related to a compensatory
induction of Nrf2 mRNA transcription that is stimulated by the
compound itself and/or the rapid depletion of Nrf2 protein.
Notably, concentrations of brusatol that caused the depletion of
Nrf2 protein were minimally cytotoxic, as demonstrated by quan-
tiﬁcation of cellular ATP content (Fig. 1E). Taken together, these
data demonstrate that brusatol potently induces the rapid and
transient depletion of Nrf2 via a posttranscriptional mechanism.
Functional consequences of Nrf2 inhibition by brusatol
Consistent with the ability of brusatol to deplete Nrf2 protein,
and the well-characterized role of Nrf2 in regulating the basal and
inducible expression of cytoprotective genes, we detected signiﬁ-
cant time-dependent decreases in the mRNA levels of the classical
Nrf2 target genes Nqo1 and Gclm after exposure of Hepa-1c1c7 cells
to 300 nM brusatol for up to 12 h, with evidence for a compensa-
tory increase in the expression of these genes 24 h after exposure to
the compound (Fig. 2). These results indicate that the rapid and
transient depletion of Nrf2 provoked by brusatol causes a functional
downregulation of Nrf2-sensitive cytoprotective processes.
Inhibition of chemically induced Nrf2 by brusatol
A potential therapeutic application of an Nrf2 inhibitor such as
brusatol is the downregulation of Nrf2 pathway components in
cells harboring constitutively high levels of the transcription
factor. Such a phenomenon is increasingly linked with the devel-
opment of chemoresistance in cancer cells [11,16]. To examine the
ability of brusatol to deplete elevated levels of Nrf2, we used the
chemical inducers CDDO-Me (also known as bardoxlone methyl),
Fig. 2. Functional consequences of Nrf2 inhibition by brusatol. The mRNA levels of
the Nrf2 target genes Nqo1 and Gclm in Hepa-1c1c7 cells exposed to 300 nM
brusatol for the indicated times are shown, as determined by RT-qPCR. Nqo1 and
GclmmRNA levels were normalized to the loading control, Gapdh, and expressed as
a percentage of the Nqo1 and Gclm levels detected at 0 h. All data represent the
mean þ SD of n¼3 independent experiments. Statistical analyses were performed
using an unpaired t test (*Po0.05, **Po0.01, ***Po0.001 vs 0-h control).
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Fig. 3. Inhibition of chemically induced Nrf2 by brusatol. (A and B) Nrf2 protein levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to (A) vehicle or 300 nM
brusatol for 2 h, followed by the indicated concentrations of CDDO-Me for 1 h, or (B) the indicated concentrations of CDDO-Me for 1 h, followed by 300 nM brusatol for 2 h, as
determined by immunoblotting. (C) Nrf2–Venus levels in SK-N-AS cells exposed to 100 nM CDDO-Me for 1 h, followed by 300 nM brusatol for the indicated times. Still images were
captured from the real-time data presented in Supplementary Video 1. (D and E) Nrf2 protein levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to vehicle or
300 nM brusatol for 2 h, followed by the indicated concentrations of (D) NEM or (E) IAA for 1 h. All blots shown are representative of three independent experiments. Nrf2 levels
were quantiﬁed by densitometry, normalized to the loading control, β-actin, and expressed as a percentage of the Nrf2 level detected in vehicle-exposed cells. Data represent the
mean þ SD of n¼3 independent experiments. Statistical analysis was performed using an unpaired t test (*Po0.05, **Po0.01 vs CDDO-Me, IAA, or NEM alone).
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N-ethylmaleimide (NEM), and IAA. Pretreatment of Hepa-1c1c7
cells with 300 nM brusatol for 2 h, followed by exposure to a range
of concentrations of CDDO-Me for 1 h, markedly inhibited the
ability of the latter compound to provoke Nrf2 accumulation
(Fig. 3A). Moreover, brusatol was able to deplete Nrf2 when
applied to cells in which the transcription factor had already
accumulated after pretreatment with CDDO-Me (Fig. 3B). This
ﬁnding was conﬁrmed by real-time ﬂuorescence imaging of
human SK-N-AS neuroblastoma cells engineered to stably express
Venus-tagged Nrf2 under control of an endogenous human pro-
moter. In these cells, CDDO-Me provoked a substantial accumula-
tion of Nrf2–Venus within 1 h, yet subsequent addition of brusatol
stimulated a rapid and transient depletion of Nrf2–Venus (Fig. 3C
and Supplementary Vedeo 1). To ensure that the above observa-
tions were not speciﬁc to CDDO-Me, we pretreated Hepa-1c1c7
cells with 300 nM brusatol for 2 h and stimulated Nrf2 accumula-
tion by subsequent exposure to a range of concentrations of the
electrophiles NEM or IAA for 1 h. Under these conditions, brusatol
markedly attenuated the ability of NEM or IAA to induce Nrf2
(Figs. 3D and E). Consistent with these ﬁndings, and in a demon-
stration of the translational relevance of the data generated with
Hepa-1c1c7 cells, brusatol was also shown to inhibit the accumu-
lation of Nrf2 and its downstream target Nqo1 when applied to
freshly isolated primary human hepatocytes in which the tran-
scription factor had been induced via pretreatment with CDDO-Me
(Fig. 4). Taken together, these data conﬁrm that brusatol is capable
of stimulating the depletion of elevated levels of Nrf2 in
mammalian cells.
Supplementary material related to this article can be found
online at http://dx.doi.org/10.1016/j.freeradbiomed.2014.11.003.
Brusatol sensitizes mammalian cells to chemical stress
In light of our data demonstrating the ability of brusatol to
inhibit Nrf2 signaling, and given the well-deﬁned role of Nrf2 in
regulating the activity of cytoprotective processes in mammalian
cells, we sought to test the hypothesis that brusatol-mediated
depletion of Nrf2 would sensitize Hepa-1c1c7 cells to the deleter-
ious effects of chemical stress provoked by model electrophiles.
Indeed, pretreatment of cells with brusatol enhanced the cyto-
toxicity elicited by DNCB, IAA, and NAPQI (Figs. 5A–C). Notably,
increasing the duration of the brusatol pretreatment period
Fig. 4. Inhibition of Nrf2 by brusatol in primary human hepatocytes. Nrf2 and Nqo1
protein levels in whole-cell lysates prepared from freshly isolated primary human
hepatocytes exposed to 100 nM CDDO-Me for 1 h, followed by 100 nM brusatol for
the remainder of the indicated times, are shown as determined by immunoblotting.
The proteasome inhibitor MG132 was used as a positive control for Nrf2 accumulation.
The blots shown are from samples derived from donor PHH1 and are representative of
experiments performed using cells isolated from four donors (PHH1–4). Nrf2 levels
in cells exposed to CDDO-Me and brusatol for a total of 25 h were quantiﬁed by
densitometry, normalized to the loading control, β-actin, and expressed as a percentage
of the Nrf2 level detected in vehicle-exposed cells. Statistical analysis was performed
using an unpaired t test (*Po0.05 vs CDDO-Me alone).
Fig. 5. Brusatol sensitizes mammalian cells to chemical stress. ATP content in
Hepa-1c1c7 cells exposed to 300 nM brusatol for the indicated times, followed by
the indicated concentrations of (A) DNCB for 6 h, (B) IAA for 6 h, or (C) NAPQI for
12 h is shown. ATP levels are expressed as a percentage of the ATP content of
vehicle-exposed cells. Data represent the mean þ SD of n¼3 independent
experiments. Statistical analysis was performed using an unpaired t test
(*Po0.05, **Po0.01 vs vehicle control).
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resulted in a greater potentiation of cytotoxicity in each case
(Figs. 5A–C). Therefore, these data indicate that brusatol is capable
of sensitizing mammalian cells to chemical stress.
The inhibitory effect of brusatol is speciﬁc to Nrf2 but not dependent
on the canonical mechanisms of Nrf2 degradation
An understanding of the mechanism(s) by which brusatol
inhibits Nrf2 is critical to evaluating the beneﬁt:risk ratio of the
compound, and other Nrf2 inhibitors, in therapeutic contexts. We
noted that brusatol and structurally related compounds have been
shown previously to inhibit general protein synthesis at micro-
molar concentrations [17,18]. We also noted that, among the panel
of proteins measured by Ren et al. [12] in their recent report, only
c-Myc, which has a relatively short half-life of 20–30 min, was
depleted in response to brusatol, albeit to a lesser degree than
Nrf2. Given that Nrf2 also has a relatively short half-life (15–
30 min in the absence of chemical or oxidative stimuli), we
examined the effects of brusatol on other proteins with short
half-lives, to determine the speciﬁcity of brusatol toward Nrf2.
Importantly, brusatol had no discernible effect on the basal levels
of cyclin A, HIF-1α, p53, or survivin under conditions that were
associated with substantial Nrf2 depletion (Fig. 6). These data
indicate that the inhibitory effect of brusatol is speciﬁc, and not a
consequence of a broader effect on protein synthesis, at the
nanomolar concentrations required to deplete Nrf2.
Given that our data demonstrated an ability of brusatol to
deplete Nrf2 protein in a rapid and posttranscriptional manner
(Fig. 1D), we examined the dependence of brusatol's inhibitory
action on the classical mechanisms of Nrf2 protein regulation,
namely Keap1-mediated repression [3], and degradation via the
proteasome [19] and autophagy [20] systems. After exposure of
Hepa-1c1c7 cells to 300 nM brusatol for up to 2 h, conditions that
were sufﬁcient to cause maximal depletion of Nrf2 (Fig. 1C), there
was no overt change in the level of Keap1 protein (Fig. 7A),
indicating that the marked decrease in Nrf2 was not caused by a
concomitant increase in the level of its cytosolic inhibitor. Further-
more, in cells transfected with Keap1-targeting siRNA, which
depleted Keap1 protein by 90% and caused a substantial accumu-
lation of Nrf2 (Fig. 7B), brusatol was able to deplete Nrf2 as
efﬁciently as in cells transfected with a scrambled, nontargeting
control siRNA (Fig. 7B). These data indicate that brusatol provokes
the depletion of Nrf2 independent of Keap1.
To examine the potential for brusatol to directly augment the
proteasomal degradation of Nrf2, we determined the effects of the
compound on the chymotrypsin-, trypsin-, and caspase-like activ-
ities of human 20S proteasome in vitro. In each case, brusatol had
no discernible effect on proteasome activity (Fig. 7C). Consistent
with these ﬁndings, brusatol was able to deplete Nrf2 when added
to cells in which Nrf2 levels had been increased via pretreat-
ment with the proteasomal inhibitor MG132 (Fig. 7D). Therefore,
brusatol appears to deplete Nrf2 via a process that does not
involve its enhanced proteasomal degradation. A major alternative
cellular mechanism of protein degradation is macroautophagy.
Processing of p62 is commonly used as an indicator of augmented
autophagy [21], and p62 has been shown to physically interact with
Keap1 and direct the Keap1–Nrf2 complex to the autophagy machin-
ery [20]. However, we found no evidence for a change in the level of
p62 under conditions of maximal Nrf2 depletion by brusatol (Fig. 7E).
Furthermore, although chemical inhibition of autophagy (by baﬁlo-
mycin or ammonium chloride) stimulated an accumulation of p62,
and to a lesser degree Nrf2, brusatol was still able to provoke the
maximal depletion of Nrf2 under these conditions (Fig. 7F). There-
fore, these data indicate that brusatol provokes the depletion of Nrf2
via a mechanism that is not dependent on Keap1 and the proteaso-
mal and autophagic protein degradation systems.
Inhibition of Nrf2 by brusatol is not dependent on the activation of
p38 MAPK, AKT, ERK1/2, or JNK1/2 signaling
In addition to Nrf2, protein kinases are among the most
sensitive cellular signaling components that are modulated by
chemical perturbation. Therefore, we examined the ability of
brusatol to alter the activity of several protein kinases that have
been implicated in Nrf2 signaling. Notably, brusatol provoked a
rapid increase in the phosphorylation of p38 MAPK, AKT, ERK1/2,
and JNK1/2 in parallel with depletion of Nrf2 (Fig. 8A). However,
the inhibitory effect of brusatol on Nrf2 was shown to be
independent of these events, as preincubation of cells with the
kinase inhibitors SB203580 (p38 MAPK), LY294002 (AKT),
CT99021 (GSK3β), U0126 (ERK1/2), and SP600125 (JNK1/2) had
no discernible effect on the ability of brusatol to deplete Nrf2
(Fig. 8B). Therefore, brusatol inhibits Nrf2 via a mechanism that is
not dependent on the activation of p38 MAPK, AKT, ERK1/2, or
JNK1/2 signaling. Taken together with our data demonstrating that
brusatol's inhibitory effect on Nrf2 is independent of Keap1 and
the proteasomal and autophagic protein degradation systems,
these ﬁndings imply the involvement of a novel means of Nrf2
regulation in the mechanism of action of this compound.
Discussion
To date, the majority of translational research on Nrf2 has
focused on its role in protection against disease-inducing insults
and the potential value of pharmacologically activating Nrf2
signaling in the prevention and/or treatment of various patholo-
gies [22]. However, prompted by evidence that hyperactivation of
Nrf2 signaling is associated with the progression of cancer and
development of chemoresistance [11], researchers have recently
begun to search for chemical inhibitors of Nrf2 and to examine
their pharmacological mechanisms of action. Consistent with
recent reports [12–14], here we have shown that the natural
quassinoid brusatol provokes a rapid and transient depletion of
Nrf2 protein, through a posttranscriptional mechanism, in mouse
Hepa-1c1c7 hepatoma cells and freshly isolated primary human
hepatocytes and sensitizes mammalian cells to the cytotoxic
effects of model electrophiles. These ﬁndings verify brusatol as a
valuable experimental tool for studying the cytoprotective func-
tions of Nrf2, particularly when the genetic manipulation of Nrf2 is
not suitable or favorable.
The development of chemoresistance is a barrier to the effective
management of various forms of cancer [23]. In light of the recently
established role of Nrf2 in drug resistance in cancer cell lines and
Fig. 6. Brusatol does not provoke the general depletion of short-half-life proteins in
Hepa-1c1c7 cells. Cyclin A, HIF-1α, p53, and survivin protein levels in whole-cell
lysates prepared from Hepa-1c1c7 cells exposed to 300 nM brusatol for the
indicated times are shown, as determined by immunoblotting. All blots shown
are representative of three independent experiments.
A. Olayanju et al. / Free Radical Biology and Medicine 78 (2015) 202–212208
Fig. 7. Inhibition of Nrf2 by brusatol is not dependent on the canonical mechanisms of Nrf2 degradation. (A) Keap1 protein levels inwhole-cell lysates prepared from Hepa-1c1c7 cells
exposed to 300 nM brusatol for the indicated times, as determined by immunoblotting. (B) Keap1 and Nrf2 protein levels in whole-cell lysates prepared from Hepa-1c1c7 cells
transfected with a scrambled, nontargeting control siRNA (si-CON) or a Keap1-targeting siRNA (si-KEAP1) for 48 h, followed by exposure to the indicated concentrations of brusatol for
2 h. (C) Effects of incubation with the indicated concentrations of brusatol or the proteasome inhibitor MG132, for the indicated times, on the chymotrypsin (Suc-LLVY-AMC)-, trypsin
(Boc-LSTR-AMC)-, and caspase (Z-LLE-AMC)-like activities of human 20S proteasome. (D) Nrf2 protein levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to the
indicated concentrations of MG132 for 1 h, followed by 300 nM brusatol for 2 h. (E) p62 protein levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to 300 nM
brusatol for the indicated times. Lysates prepared from mock-transfected (-ve) and p62-transfected (þve) HEK293T cells were loaded as controls. (F) Nrf2 and p62 protein levels in
whole-cell lysates prepared from Hepa-1c1c7 cells exposed to 30 nM baﬁlomycin A1 or 10 mM ammonium chloride (NH4Cl) for 16 h, followed by the indicated concentrations of
brusatol for 2 h. All blots shown are representative of three independent experiments. Nrf2 levels were quantiﬁed by densitometry, normalized to the loading control, β-actin, and
expressed as a percentage of the Nrf2 level detected in vehicle-exposed cells. Data represent the mean þ SD of n¼3 independent experiments. Statistical analysis was performed using
an unpaired t test (*Po0.05, **Po0.01, ***Po0.001 vs vehicle control or MG132 alone).
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Fig. 8. Inhibition of Nrf2 by brusatol is not dependent on the activation of p38 MAPK, AKT, ERK1/2, or JNK1/2 signaling. (A) Nrf2 and phospho-p38 MAPK, AKT, ERK1/2, and
JNK1/2 levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to 300 nM brusatol for the indicated times, as determined by immunoblotting. (B) Nrf2 protein
levels in whole-cell lysates prepared from Hepa-1c1c7 cells exposed to the indicated concentrations of SB203580 (p38 MAPK), LY294002 (AKT), CT99021 (GSK3β), or
SP600125 (JNK1/2) or 5 mM U0126 (ERK1/2) for 1 h, followed by 300 nM brusatol for 2 h. All blots shown are representative of three independent experiments. Nrf2 or
protein kinase levels were quantiﬁed by densitometry, normalized to the loading control, β-actin, and expressed as a percentage of the Nrf2 or protein kinase level detected
at 0 h or in vehicle-exposed cells. Data represent the mean þ SD of n¼3 independent experiments. Statistical analysis was performed using an unpaired t test (*Po0.05,
**Po0.01, ***Po0.001 vs vehicle or 0 h control).
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tissues [11], there is much interest in the potential value of
inhibiting Nrf2 to enhance the efﬁcacy of established and novel
chemotherapeutic agents. Zhang and colleagues recently demon-
strated the ability of brusatol to ameliorate chemoresistance in both
in vitro and in vivo cancer models [12–14]. However, given the
established role of Nrf2 as a key regulator of cell defense against
endogenous and exogenous chemical and oxidative insults, it is
possible that indiscriminate inhibition of Nrf2 may sensitize non-
target cells to the cytotoxic effects of cancer drugs, thereby exacer-
bating adverse effects. Such a concept is supported by our ﬁnding
that brusatol enhances the cytotoxic effects of model electrophiles
toward mammalian cells in vitro. Analogous to the drive to target
chemotherapy based on the cell type and/or molecular landscape of
speciﬁc cancers, an ability to direct the pharmacological inhibition
of Nrf2 by brusatol and other compounds to relevant cells may
provide an opportunity to enhance therapeutic efﬁcacy and cir-
cumvent the potential for enhancement of off-target toxicity. Even if
such an approach is realized, the risk:beneﬁt ratio of inhibiting Nrf2
needs greater consideration before it can be developed into a viable
strategy for the treatment of chemoresistant forms of cancer and
other diseases in which aberrant Nrf2 signaling plays a role.
Although brusatol and structurally related compounds can
serve as general protein synthesis inhibitors at micromolar con-
centrations [17,18], the lack of effect of brusatol on the levels of
other proteins [12], including those with short (cyclin A, HIF-1α,
p53, and survivin) and long (Keap1, p62, and actin) half-lives
studied here, indicates that the depletion of Nrf2 provoked by
nanomolar concentrations of brusatol is speciﬁc and not a con-
sequence of a broader effect on protein synthesis. Previous work
has demonstrated that brusatol is able to deplete Nrf2 in cancer
cell lines harboring wild-type or mutated Keap1 [12]. This ﬁnding
indirectly implied that the inhibitory action of brusatol is not
dependent on Keap1. Here, we have provided direct evidence for
this notion, through siRNA knockdown of Keap1, which had no
discernible effect on the ability of brusatol to deplete Nrf2 in a
rapid and transient manner. These data highlight the potential
value of brusatol as an inhibitor of Nrf2 signaling in contexts, such
as cancer [11], in which the negative regulation of Nrf2 by Keap1
has been circumvented. We have also demonstrated that the
classical cellular mechanisms of protein degradation, namely the
ubiquitin–proteasome system and autophagy, are dispensable for
brusatol's inhibitory action toward Nrf2. Although these observa-
tions do provide valuable insights into the means by which
brusatol downregulates Nrf2 signaling, and imply the involvement
of a novel means of Nrf2 regulation in the pharmacodynamic
effects of this compound, further investigation will be required to
reveal the detailed underlying mechanism(s). Recently, it has been
suggested that an as-yet unidentiﬁed molecular process represses
the translation of Nrf2 mRNAwithin the open reading frame of the
gene [24]. It is possible that brusatol could temporarily augment
this translational repression. Indeed, this would account for our
observation that the rapid and substantial depletion of Nrf2
protein provoked by brusatol is not preceded by a discernible
decrease in the level of Nrf2 mRNA. Further work is needed to test
this hypothesis.
A notable feature of brusatol's inhibitory action toward Nrf2 is
the transient nature of its effect and the compensatory increase in
the level of Nrf2 and its target genes 24 h after exposure to the
compound. A similar ﬁnding has been documented in A549 cells
by Ren et al. [12]. Knowledge of the chemical and/or molecular
mechanisms that determine the transient nature of brusatol's
inhibitory action toward Nrf2 may provide an opportunity for
chemical tuning of the compound, to provide a pharmacological
antagonist of Nrf2 with long-lasting effects, so as to minimize the
need for repeated dosing in vivo. On the other hand, Zhang and
colleagues have reported signiﬁcant decreases in Nrf2 pathway
activity and associated increases in chemotherapeutic efﬁcacy in
mice after chronic administration of brusatol [12,14], indicating
that the transient nature of brusatol's inhibitory effect on Nrf2
signaling can be overcome through repeated dosing in vivo. These
ﬁndings conﬁrm that brusatol can repress Nrf2 signaling in
laboratory animals, whereas we have shown that brusatol can
provoke the depletion of Nrf2 in freshly isolated primary human
hepatocytes, demonstrating the translational relevance of our
detailed investigations in mouse Hepa-1c1c7 hepatoma cells.
In summary, we have shown that brusatol provokes a rapid and
transient depletion of Nrf2 protein and consequent downregula-
tion of Nrf2-regulated cell defense processes, thereby sensitizing
mammalian cells to chemical stress. Although these ﬁndings verify
brusatol as a useful experimental tool for the inhibition of Nrf2
signaling, they also highlight the potential for therapeutic inhibi-
tion of Nrf2 to alter the risk of adverse events by reducing the
capacity of nontarget cells to buffer against chemical and oxidative
insults. A current lack of detail makes it difﬁcult to establish the
existence of a common mechanism of action for the small number
of Nrf2 inhibitors reported to date, including brusatol, retinoic acid
receptor α agonists [25], leutolin [26], and trigonelline [27]. The
identiﬁcation of a unifying mechanism would facilitate high-
throughput screening of compound libraries, which may reveal
novel inhibitors of Nrf2. A better mechanistic understanding
would also inform a rational assessment of the risk:beneﬁt ratio
of inhibiting Nrf2 in relevant therapeutic contexts, which is
essential if compounds such as brusatol are to be developed into
efﬁcacious and safe drugs.
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